These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 17412745)
1. Facilitating and understanding the family's choice of injection device for growth hormone therapy by using conjoint analysis. Ahmed SF; Smith WA; Blamires C Arch Dis Child; 2008 Feb; 93(2):110-4. PubMed ID: 17412745 [TBL] [Abstract][Full Text] [Related]
3. Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads. Hey-Hadavi J; Pleil A; Deeb LC; Fuqua JS; Silverman LA; Reiner B; Newfield R; Rajicic N; Wajnrajch MP; Cara JF Clin Ther; 2010 Nov; 32(12):2036-47. PubMed ID: 21118739 [TBL] [Abstract][Full Text] [Related]
4. Medical decision-making and the patient: understanding preference patterns for growth hormone therapy using conjoint analysis. Singh J; Cuttler L; Shin M; Silvers JB; Neuhauser D Med Care; 1998 Aug; 36(8 Suppl):AS31-45. PubMed ID: 9708581 [TBL] [Abstract][Full Text] [Related]
6. Patient acceptance of a novel electronic auto-injector device to administer recombinant human growth hormone: results from an open-label, user survey of everyday use. Dahlgren J; Veimo D; Johansson L; Bech I Curr Med Res Opin; 2007 Jul; 23(7):1649-55. PubMed ID: 17559757 [TBL] [Abstract][Full Text] [Related]
7. Parent preference in Switzerland for easy-to-use attributes of growth hormone injection devices quantified by willingness to pay. Meinhardt U; Eiholzer U; Seitz L; Bøgelund M; Kappelgaard AM Expert Rev Med Devices; 2014 Jan; 11(1):31-8. PubMed ID: 24308742 [TBL] [Abstract][Full Text] [Related]
8. Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: a noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patients. Pfützner A; Hartmann K; Winter F; Fuchs GS; Kappelgaard AM; Rohrer TR Clin Ther; 2010 Oct; 32(11):1918-34. PubMed ID: 21095487 [TBL] [Abstract][Full Text] [Related]
9. Indications for recombinant human growth hormone and evaluation of available recombinant human growth hormone devices: implications for managed care organizations. Dunn JD; Nickman NA Am J Manag Care; 2011 Dec; 17 Suppl 18():eS16-22. PubMed ID: 22590764 [TBL] [Abstract][Full Text] [Related]
11. Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients. Kappelgaard AM; Mikkelsen S; Knudsen TK; Fuchs GS J Pediatr Endocrinol Metab; 2011; 24(7-8):489-96. PubMed ID: 21932587 [TBL] [Abstract][Full Text] [Related]
12. A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis. Shingler SL; Swinburn P; Ali S; Perard R; Lloyd AJ J Med Econ; 2013 Aug; 16(8):1036-42. PubMed ID: 23730944 [TBL] [Abstract][Full Text] [Related]
13. Psychological responses to the needle-free Medi-Jector or the multidose Disetronic injection pen in human growth hormone therapy. Verrips GH; Hirasing RA; Fekkes M; Vogels T; Verloove-Vanhorick SP; Delemarre-Van de Waal HA Acta Paediatr; 1998 Feb; 87(2):154-8. PubMed ID: 9512200 [TBL] [Abstract][Full Text] [Related]
14. Are needle-free injections a useful alternative for growth hormone therapy in children? Safety and pharmacokinetics of growth hormone delivered by a new needle-free injection device compared to a fine gauge needle. Dörr HG; Zabransky S; Keller E; Otten BJ; Partsch CJ; Nyman L; Gillespie BK; Lester NR; Wilson AM; Hyrén C; van Kuijck MA; Schuld P; Schoenfeld SL J Pediatr Endocrinol Metab; 2003 Mar; 16(3):383-92. PubMed ID: 12705363 [TBL] [Abstract][Full Text] [Related]
15. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Schaarschmidt ML; Schmieder A; Umar N; Terris D; Goebeler M; Goerdt S; Peitsch WK Arch Dermatol; 2011 Nov; 147(11):1285-94. PubMed ID: 22106115 [TBL] [Abstract][Full Text] [Related]
16. Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth. Desrosiers P; O'Brien F; Blethen S Pediatr Endocrinol Rev; 2005 Feb; 2 Suppl 3():327-31. PubMed ID: 16456500 [TBL] [Abstract][Full Text] [Related]
17. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Haverkamp F; Johansson L; Dumas H; Langham S; Tauber M; Veimo D; Chiarelli F Clin Ther; 2008 Feb; 30(2):307-16. PubMed ID: 18343269 [TBL] [Abstract][Full Text] [Related]
18. [Administration of the hormone and the patient's experience]. Boiteux A; Fabregas B Soins Pediatr Pueric; 2000; (193):31-2. PubMed ID: 11040798 [No Abstract] [Full Text] [Related]
19. Optimum method for administration of biosynthetic human growth hormone: a randomised crossover trial of an Auto Injector and a pen injection system. Stanhope R; Albanese A; Moyle L; Hamill G Arch Dis Child; 1992 Aug; 67(8):994-7. PubMed ID: 1520018 [TBL] [Abstract][Full Text] [Related]
20. The effect of information on preferences stated in a choice-based conjoint analysis. van Til JA; Stiggelbout AM; Ijzerman MJ Patient Educ Couns; 2009 Feb; 74(2):264-71. PubMed ID: 18954956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]